Lynch, Mark
The University of Texas MD Anderson Cancer Center · Institut Gustave Roussy · University of Chicago · Bristol-Myers Squibb (United States) · Centre Léon Bérard · Dana-Farber Cancer Institute · University of Pittsburgh Medical Center · Centre Antoine Lacassagne · Stanford University
2 papers on CoChatORCID 0000-0002-8476-4854
Most cited papers
- Verified
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine
Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers
Cited by 5,101
- Verified
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer
Angiogenesis and VEGF in CancerColorectal Cancer Treatments and Studies
Cited by 1,355
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free